Ladies and gentlemen, thank you for the opportunity to present an exciting investment opportunity! We introduce Spore.Bio, a French AI startup revolutionizing the detection of bacteria in food, drugs, and cosmetics. With its recent Series A funding of $23 million, the company is poised for rapid expansion and implementation of cutting-edge AI-based solutions.

The market opportunity is vast, as industries are demanding faster, more accurate methods for microbiological testing.

Spore.Bio’s technology addresses this need by significantly reducing testing times while enhancing detection capabilities. Led by visionary co-founder Amine Raji, Spore.Bio is at the forefront of transforming food safety standards and setting new benchmarks for hygiene.

Our business model focuses on providing AI-driven, photonics-based testing solutions for various industries. We aim to build partnerships with key players in food, pharmaceutical, and cosmetics sectors, offering our game-changing technology on a subscription basis. This approach ensures recurring revenue and positions Spore.Bio for sustained growth.

Spore.Bio’s competitive advantages include its advanced AI technology, industry expertise, and strategic partnerships. The company’s impressive funding success is a testament to its potential for market disruption and strong investor confidence.

Projections indicate substantial potential returns as Spore.Bio expands its client base and revolutionizes microbiological testing. We invite you to join us on this journey and discover the immense potential of investing in Spore.Bio – together, we can shape the future of food safety and hygiene.

Thank you for considering this opportunity. We look forward to discussing how we can achieve success together and transform industries with Spore.Bio’s pioneering technology!